Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Breast Neoplasms × EC regimen × Clear all

Phase

Phase 3 2 Phase NA 1 Phase 2/3 1 Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Small Cell Lung Carcinoma 1 Carcinoma, Neuroendocrine 1 Breast Neoplasms 1

Interventions

Capecitabine 15 Paclitaxel 11 Docetaxel 10 Cyclophosphamide 10 Epirubicin 8 Gemcitabine 7 Letrozole 6 Doxorubicin 6 Carboplatin 6 Trastuzumab 5 Vinorelbine 4 pertuzumab 3 exemestane 3 Cisplatin 3 AC protocol 3 130-nm albumin-bound paclitaxel 3 Thiotepa 2 Taxes 2 Tamoxifen 2 Neoadjuvant Therapy 2 Melatonin 2 Lapatinib 2 Goserelin 2 Fluorouracil 2 Drug Therapy 2 Albumin-Bound Paclitaxel 2 Ado-Trastuzumab Emtansine 2 taxane 1 soluble LAG-3 protein, human 1 pyrotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01204437 2016-02-10

ICE-II

GBG Forschungs GmbH

Phase 2/3 Completed

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡